[{"id":"868293a8-a265-41a4-8e63-93c5f8993ec3","acronym":"","url":"https://clinicaltrials.gov/study/NCT02704858","created_at":"2021-02-25T12:16:38.279Z","updated_at":"2024-07-02T16:35:19.174Z","phase":"Phase 1/2","brief_title":"Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma","source_id_and_acronym":"NCT02704858","lead_sponsor":"Neonc Technologies, Inc.","biomarkers":" IDH1","pipe":" | ","alterations":" IDH1 mutation","tags":["IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e perillyl alcohol (NEO100)"],"overall_status":"Recruiting","enrollment":" Enrollment 49","initiation":"Initiation: 04/08/2016","start_date":" 04/08/2016","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-02-15"}]